Chinese inhaled drug developer and CDMO CF PharmTech has raised $65M in a Series D financing round led by Future Industry Investment Fund (managed by SDIC Fund Management), the company said. The money is to be used for development of the company’s own OINDPs and for expansion of its CDMO services.
SDIC Fund Management Managing Direct Hai Lu said, “Drug delivery via pulmonary route bears significant technical challenges and it takes extraordinary effort to bring inhalation products to the market. CF PharmTech’s high caliber team has proved their ability to attract top industry talents to develop inhalation products for the global market. We are confident that they will achieve their business mission in the near future.”
According to the company’s announcement, “CF PharmTech aims to provide quality and cost-effective inhalation products for domestic market, and seeks strategic partnerships to co-develop and commercialize its products globally.”
Read the CF PharmTech press release.
